Flatgaard J E, Bauer K E, Kauvar L M
Terrapin Technologies, Inc., South San Francisco, CA 94080.
Cancer Chemother Pharmacol. 1993;33(1):63-70. doi: 10.1007/BF00686025.
A systematically diversified set of peptide analogs of the reaction product of glutathione with an electrophilic substrate have been tested as isozyme-specific inhibitors of human glutathione-S-transferase (GST). The potency of the best of the inhibitors is in the 0.5 to 20 micromolar range, with kinetics indicative of competitive inhibition with glutathione at the active site. The specificity observed among three recombinant-derived GST isozymes at both low and high potency ranged from negligible to high (at least 20-fold over the next most sensitive isozyme). These results define a novel strategy for the design of drugs targeting cells with elevated levels of particular GST isozymes, such as tumor cells for which elevated levels of GST are believed to be an important cause of chemotherapeutic drug resistance.
谷胱甘肽与亲电底物反应产物的一系列经过系统多样化设计的肽类似物,已作为人谷胱甘肽-S-转移酶(GST)的同工酶特异性抑制剂进行了测试。最佳抑制剂的效力在0.5至20微摩尔范围内,其动力学表明在活性位点与谷胱甘肽存在竞争性抑制作用。在低效力和高效力条件下,三种重组衍生的GST同工酶之间观察到的特异性范围从可忽略不计到高度特异性(至少比下一个最敏感的同工酶高20倍)。这些结果为设计针对特定GST同工酶水平升高的细胞(如肿瘤细胞,据信GST水平升高是化疗耐药的重要原因)的药物定义了一种新策略。